Jenburkt Pharmaceuticals Ltd.

Jenburkt Pharmaceuticals Ltd., a speciality pharmaceutical formulations manufacturer operating across 13 countries, delivered a mixed performance in Q4 FY26 (Mar'26), with net profit surging 27.05% quarter-on-quarter to ₹10.85 crores despite modest revenue growth of 3.74%. The ₹510 crore market capitalisation company demonstrated impressive margin expansion, with operating profit margin (excluding other income) reaching a seven-quarter high of 31.93%, up from 17.25% in the previous quarter. The stock responded positively to the results, gaining 7.03% on May 06, 2026, to close at ₹1,150.00, reflecting investor confidence in the company's operational efficiency improvements.

Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook.

Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 10 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Jenburkt Pharmaceuticals Ltd. touched a new 52-week low of Rs.944 today, marking a significant price level for the stock amid a mixed market environment. Despite outperforming its sector by 1.72% during the trading session, the stock declined by 5.41% intraday, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Jenburkt Pharmaceuticals Ltd., a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 3 February 2026. This shift reflects a comprehensive reassessment across four critical parameters: Quality, Valuation, Financial Trend, and Technicals. The downgrade comes amid rising valuation concerns, subdued financial performance, and a cautious technical outlook, despite some long-term growth strengths.

Jenburkt Pharmaceuticals Ltd. has experienced a notable shift in its valuation parameters, moving from a fair to an expensive rating, prompting a downgrade in its Mojo Grade from Hold to Sell. This change reflects evolving market perceptions amid mixed financial metrics and relative performance against peers and benchmarks.

Jenburkt Pharmaceuticals Ltd., a Mumbai-based speciality pharmaceutical formulations manufacturer, reported a concerning quarter-on-quarter decline in profitability for Q3 FY26, with net profit falling 41.63% to ₹5.93 crores from ₹10.16 crores in the previous quarter. Despite posting year-on-year revenue growth of 16.62%, the company's operating margins contracted sharply to 17.25% from 28.75% in Q2 FY26, marking the lowest quarterly operating margin in recent periods. The stock, with a market capitalisation of ₹458 crores, closed at ₹1,105.00 on February 3, 2026, gaining 6.83% on the day but remains down 13.39% over the past three months.

Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 February 2026, providing investors with the latest insights into its performance and outlook.

Jenburkt Pharmaceuticals Ltd. is currently rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's present position as of 23 January 2026, providing investors with the most recent and relevant data to assess the company’s outlook.

Jenburkt Pharmaceuticals Ltd., a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 9 January 2026. This shift reflects a confluence of deteriorating technical indicators, valuation pressures, and subdued long-term financial growth, despite some recent positive quarterly results. Investors are advised to carefully consider these factors amid the stock’s underperformance relative to broader market benchmarks.